CD8A and neoplasm: This specific CD8+ T cell subset was found to be tumor antigen specific [67] and to proliferate in response to the PD-1 blockade, hence representing a proposed main target of anti-PD-1 therapy and an indicator of increased therapeutic responsiveness [56,68].